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Abstract
Background—In addition to preventing hospitalizations and deaths due to influenza, influenza 
vaccination programs can reduce the burden of outpatient visits for influenza. We estimated the 
incidence of medically-attended influenza at three geographically diverse sites in the United 
States, and the cases averted by vaccination, for the 2013/14 through 2015/16 influenza seasons.
Methods—We defined surveillance populations at three sites from the United States Influenza 
Vaccine Effectiveness Network. Among these populations, we identified outpatient visits 
laboratory-confirmed influenza via active surveillance, and identified all outpatient visits for acute 
respiratory illness from healthcare databases. We extrapolated the total number of outpatient visits 
for influenza from the proportion of surveillance visits with a positive influenza test. We combined 
estimates of incidence, vaccine coverage, and vaccine effectiveness to estimate outpatient visits 
averted by vaccination.
Results—Across the three sites and seasons, incidence of medically attended influenza ranged 
from 14 to 54 per 1,000 population. Incidence was highest in children aged 6 months to 9 years 
(33 to 70 per 1,000) and lowest in adults aged 18-49 years (21 to 27 per 1,000). Cases averted 
ranged from 9 per 1,000 vaccinees (Washington, 2014/15) to 28 per 1,000 (Wisconsin, 2013/14).
Discussion—Seasonal influenza epidemics cause a considerable burden of outpatient medical 
visits. The United States influenza vaccination program has caused meaningful reductions in 
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outpatient visits for influenza, even in years when the vaccine is not well-matched to the dominant 
circulating influenza strain.
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INTRODUCTION
Influenza is unique among vaccine-preventable diseases, in that maintaining immunity 
requires frequent re-vaccination due to the ongoing antigenic drift of influenza viruses.[1] In 
practice, this is accomplished through yearly influenza vaccination programs, which 
represent a multi-billion dollar investment of public health resources annually.[2] The 
effectiveness of seasonal influenza vaccines, and the impact of influenza vaccination on the 
burden of disease due to influenza, can vary considerably year to year.[3] A number of 
factors contribute to this variability, including the dominant virus types/subtypes and the 
antigenic match between the virus strains included in the vaccines and the circulating virus 
strains.[4, 5] Systems to monitor influenza vaccine effectiveness (VE) have been established 
in a number of countries (e.g. [6-9]), contributing to a growing understanding of sources of 
variability in influenza VE. These studies can also identify unexpected problems with 
influenza vaccines, such as reduced effectiveness of certain vaccine virus strains from 
specific vaccine products or due to egg adaptation.[4, 10]
Although annual VE estimates serve many scientific and public health purposes, of perhaps 
greater interest to policy makers are estimates of the impact of influenza vaccination 
programs on cases, deaths, or medical encounters averted by vaccination. These estimates 
have been more difficult to obtain due to under-diagnosis of influenza in most clinical 
settings.[11] Many systems for estimating influenza VE through test-negative sampling are 
not equipped to estimate the incidence of influenza, which is needed to assess vaccine 
impact. One exception is the United States Influenza Vaccine Effectiveness (US Flu VE) 
Network.[6] Several study sites within the US Flu VE Network are able to provide 
population-based estimates of influenza incidence as well as VE. We have previously used 
the US Flu VE Network to demonstrate that ambulatory care visits averted by influenza 
vaccination can vary even when VE is relatively consistent, due to differences in influenza 
attack rates.[12] In this paper, we report the impact of influenza vaccination in the US on 
ambulatory care visits for influenza for the 2013/14 through 2015/16 influenza seasons, 
during which influenza VE varied considerably.
METHODS
Details of the US Flu VE Network have been published previously.[5, 6, 10, 13] In brief, the 
US Flu VE Network consists of five geographically distinct sites in the United States: Kaiser 
Permanente Washington in western Washington State (KPW, formerly Group Health 
Cooperative); the Marshfield Clinic in Marshfield, Wisconsin (MC); Baylor Scott and White 
Health in Temple, Texas (BSW); the University of Michigan and the Henry Ford healthcare 
systems in Ann Arbor and Detroit, Michigan; and the University of Pittsburgh partnered 
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with the UPMC (aka, the University of Pittsburgh Medical Center) in Pittsburgh, 
Pennsylvania. These sites conducted active surveillance for medically attended influenza at 
ambulatory care clinics. For the present paper, estimates of influenza incidence were taken 
from the KPW, MC, and BSW sites, for which enumerated population cohorts could be 
defined and which have demographic and healthcare utilization data available through linked 
databases. The study was approved by institutional review boards at each participating site 
and the Centers for Disease Control and Prevention (CDC).
Source populations
We defined population cohorts as of September 1st of each study year (2013–2015). For 
KPW, the source population was drawn from enrollees in KPW’s integrated group practice. 
These members receive healthcare coverage through KPW and receive medical care from 
KPW providers at KPW medical centers. Influenza surveillance was conducted at five 
(2013/14, 2015/16) or seven (2014/15) KPW medical centers. For estimating influenza 
incidence, we restricted the source population to KPW members whose primary healthcare 
provider was at one of the influenza surveillance clinics. The MC population consisted of a) 
persons with at least 12 months of residency (or since birth for those less than 12 months 
old) in the central Marshfield Epidemiology Study Area (MESA), a 14 zip code region 
centered around Marshfield, Wisconsin (all seasons), and b) non-MESA residents who have 
had ≥2 encounters within the 3 prior years at the main MC campus in Marshfield, affiliated 
hospital, or two adjacent satellite clinics (aged 6 months through 17 years in 2014/15 and all 
ages in 2015/16). MC captures at least 93% of all medical visits from MESA residents.[14] 
Influenza surveillance was conducted at primary care clinics located at the Main MC 
campus and one satellite clinic that serves MESA residents. The BSW population consisted 
of persons who had seen a BSW primary care provider for any reason within the 3 prior 
years and who lived in the Temple Population Research Area of East Bell County (defined 
by zip codes 765xx, excluding 7654x); BSW’s market share among this population covers 
approximately 72% of all outpatient visits (MG, personal communication). Influenza 
surveillance was conducted at seven BSW primary care and urgent care clinics in East Bell 
County.
We defined covariates on all subjects in the source populations using administrative 
healthcare databases as previously described.[12] Subjects were classified according to age 
on September 1st of each season (6 months to 8 years; 9 to 17 years; 18 to 49 years, 50 to 64 
years; and 65 years or older) and receipt of current season’s influenza vaccine, as defined 
from administrative healthcare databases and state immunization registries.[15] We 
identified all ambulatory care visits for presumptive medically attended acute respiratory 
illness (ARI) based on International Classification of Diseases, Version 9, Clinical 
Modification (ICD-9, for encounters prior to 1 October 2014) and Version 10 (ICD-10, for 
encounters on or after 1 October 2014) codes (Supplemental Appendix).
Influenza surveillance and laboratory testing
At each surveillance clinic, trained staff reviewed appointment schedules and consulted with 
clinical staff, as needed, to identify patients seeking care for ARI, defined as respiratory 
illness with cough of less than eight days’ duration.[13] Eligible patients were those with 
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ARI who were ≥6 months of age as of September 1st (and thus eligible for current season’s 
influenza vaccination). Study staff collected combined nasal and oropharyngeal (nasal only 
on children <2 years of age) swabs from eligible and consenting patients. Swab specimens 
were tested for influenza A and B viruses using real-time reverse transcriptase polymerase 
chain reaction (RT-PCR), with probes and primers provided by CDC. Specimens testing 
positive were further tested for virus subtype (influenza A) or lineage (influenza B). For the 
present study, US Flu VE enrollees who were not members of the site’s source population 
were excluded from the analyses. Influenza cases were defined as patients seeking outpatient 
care with a positive test for any influenza virus.
Analysis
We estimated the cumulative incidence of medically attended influenza in our study 
populations by extrapolating the total number of influenza cases in the populations from the 
number of influenza cases among the US Flu VE enrollees.[12] For this, we stratified the 
source populations into mutually exclusive groups based on study site s, age group a, 
vaccination status v, and number of medically attended acute respiratory illness (MAARI) 
visits m. Each US Flu VE enrollee was then assigned a sampling weight. US Flu VE 
enrollees with zero MAARI visits were assigned a sampling weight of 1.0; the weight for 
other enrollees was the total number of subjects in the enrollee’s (s, a, v, m) stratum divided 
by the number of US Flu VE enrollees in that stratum. Using the sampling weights, we 
estimated the total number of medically attended influenza cases in each (s, a, v, m) stratum. 
Confidence limits were calculated by bootstrapping from the source populations and the US 
Flu VE enrollees. To account for the fact that some influenza cases occurred before or after 
active surveillance at each site, we up-weighted the number of influenza cases at each site by 
the inverse of the proportion of influenza cases detected by state surveillance (Texas, 
Washington, and Wisconsin) that occurred during enrollment periods.
After calculating the cumulative incidence of influenza, we estimated the number of 
outpatient influenza visits averted by vaccination as previously described.[12] Age-specific 
estimates of influenza VE were taken from the US Flu VE Network. For each year and 
within each age stratum, we assumed influenza VE to be constant across the study sites. All 
analyses were conducted using SAS version 9.4 (SAS Institute, Cary NC).
RESULTS
The source populations ranged in size from 47,211 persons (Wisconsin, 2013/14 season) to 
162,633 persons (Washington, 2014/15 season) (Table 1). Averaged across sites and years, 
21.8% of persons in the source populations were children aged 6 months to 17 years, while 
18.6% were adults aged ≥65 years. Overall, 39.0% of source population members had 
documented receipt of influenza vaccine. Average annual influenza vaccine coverage was 
higher at the Washington and Wisconsin sites (49.6% and 45.3%, respectively) than at the 
Texas site (23.8%). The proportion of source population members with at least one MAARI 
visit ranged from 11.3% in 2013/14 to 14.4% in 2014/15.
Across the source populations, the proportion enrolled in US Flu VE Network surveillance 
ranged from 0.8% (Texas, 2013/14 season) to 2.8% (Wisconsin, 2014/15 season). The 
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proportion enrolled was highest for children aged <9 years (3.3%) and lowest for adults aged 
≥65 years (1.1%). Although all US Flu VE Network enrollees by definition had an 
ambulatory care visit for ARI, not all of these visits were assigned a MAARI ICD code, so 
between 11.2% and 12.8% of US Flu VE Network enrollees had no MAARI visit as defined 
for this analysis (Table 1).
Incidence of outpatient visits due to influenza
Averaged across the three sites, the cumulative incidence of ambulatory visits for influenza 
ranged from 24.7 (95% confidence interval [CI], 21.7 to 27.7) per 1,000 in 2013/14 to 39.2 
(95% CI, 35.9 to 42.7) per 1,000 in 2014/15. Incidence varied substantially by season, by 
age group, and by study site (Figure 1). The lowest incidence, 6.9 cases per 1,000 
population, was observed in adults aged ≥65 years of age in Wisconsin during the 2015/16 
season. The highest incidence, 76.8 cases per 1,000, was observed in children aged 6 months 
to 8 years in Texas during the 2014/15 season. The 2014/15 season, which was dominated 
by A(H3N2) viruses (Figure 1), had the highest burden of ambulatory visits for influenza of 
the three seasons.
Incidence tended to be highest among children aged 6 months to 8 years (Figure 1), with 
mean incidence of 48.9 (95% CI, 26.9 to 74.6) cases per 1,000. Incidence tended to be 
lowest in adults aged 18-49 years, with mean incidence of 23.9 (95% CI, 16.3 to 32.4) cases 
per 1,000. Incidence of ambulatory visits was not significantly different between adults aged 
50-64 years (28.9 cases per 1,000, 95% CI 15.9 to 43.2) and adults aged ≥65 years (27.8 
cases per 1,000, 95% CI 13.3 to 45.5).
Cases averted by vaccination
Overall, influenza vaccination averted an estimated 13.9 (95% CI, 3.7 to 25.9) ambulatory 
medical visits per 1,000 vaccinees. Despite having the greatest incidence of influenza, the 
2014/15 season had the fewest cases averted by vaccination (10.4 per 1,000, not statistically 
significant) (Figure 2), owing to poor vaccine effectiveness that year (Figure 2). When the 
2014/15 season was stratified by age, statistically significant cases averted were observed in 
2014/15 for all age groups except adults 18-49 years of age (Figure 2).
Across all three seasons, estimated cases averted were highest for children aged 6 months to 
8 years (21.4 cases averted per 1,000 vaccinees; 95% CI, 5.6 to 40.5) and lowest for adults 
aged 18 to 49 years (9.7 cases averted per 1,000 vaccinees; 95% CI, 4.0 to 15.6). The mean 
proportion of influenza ambulatory visits averted by vaccination was 14% (95% CI, 4 to 
23%). The proportion averted ranged from 6% (95% CI, 0 to 12%) in Texas in 2014/15 to 
40% (95% CI, 20 to 63%) in Washington in 2013/14.
Discussion
Seasonal influenza epidemics can cause substantial morbidity. In this study, we found that 
up to 5% of the population may seek outpatient care for influenza during a high severity 
influenza epidemic such as 2014/15. Extrapolated to the United States as a whole, this 
corresponds to approximately 16 million outpatient visits for influenza in a season of high 
severity. For comparison, by extrapolating from hospital-based surveillance, CDC estimated 
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that there were 16,184, 354 medical visits for influenza during the severe 2014/15 season.
[16]
Although the United States influenza vaccination program is primarily aimed at preventing 
hospitalizations and deaths due to influenza,[1] reducing the burden of ambulatory visits for 
influenza is also a public health benefit of vaccination. Based on our study results, we found 
that, on average, vaccinating 1,000 people prevented 13.9 outpatient visits for influenza (or, 
one outpatient visit was prevented for every 72 persons vaccinated). In our study 
populations, with vaccine coverage ranging from 24 to 50%, vaccination prevented an 
estimated 14% of ambulatory visits for influenza.
A major challenge for influenza vaccination programs is that the virus strains included in 
seasonal vaccines must be chosen 9 months or more prior to the start of the next influenza 
season.[17] This lead time requires public health officials to predict which candidate vaccine 
viruses will best match the viruses that will circulate in the upcoming season.[18] This can 
lead to antigenic differences between the vaccine viruses and circulating viruses, as was seen 
in the 2014/15 influenza season, when the vaccine lacked effectiveness against the 
predominant A(H3N2) virus circulating in the United States that season.[5] However, 
despite the lower degree of similarity to circulating viruses, this study suggests that the 
2014/15 influenza vaccine was still beneficial, with a statistically significant number of 
cases estimated to have been averted by vaccination for age groups at highest risk of 
complications following influenza infection. Even though the 2014/15 Northern Hemisphere 
vaccine was not effective against most circulating A(H3N2) viruses that season, the vaccine 
was still effective against circulating influenza B viruses, and vaccination reduced the 
number of ambulatory visits for influenza B virus infections.
Our estimate that influenza vaccination averted a mean of 14% of ambulatory influenza 
visits across three years is generally consistent with estimates from prior studies. We 
previously estimated cases averted in the US Flu VE Network for the 2011/12 and 2012/13 
seasons.[12] In that study, the median estimate was that 14% of ambulatory influenza cases 
were averted, ranging from 9% to 35% across study sites and seasons. A CDC study that 
inferred the number of ambulatory influenza cases in the United States from the number of 
influenza hospitalizations estimated that a median of 16% of cases were averted by 
vaccination across non-pandemic years from 2005/06 to 2010/11.[19] Updates to that study 
estimated that vaccination averted between 7.5% and 31% of ambulatory influenza cases 
from 2010/11 through 2015/16.[16, 20, 21]
Several limitations of this study are worth noting. First, our estimates of cases averted only 
include the direct effects of the vaccine among vaccinated individuals, and do not account 
for indirect effects due to reduced transmission of influenza. Thus, the true impact of 
influenza vaccination may be greater than estimated in this study. Second, our study subjects 
were mainly sampled from insured populations, for which patterns of vaccination and 
healthcare utilization may differ from uninsured populations. This may limit the 
generalizability of our results to uninsured populations. However, the insured populations 
from which our subjects were drawn are largely representative of their geographic regions in 
terms of age, sex, and race/ethnicity.[22, 23] Third, our study populations were drawn from 
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three geographic regions in the United States and may not generalize to other regions. 
Fourth, our surveillance case definition required subjects to have an acute respiratory illness 
with cough. Although cough is a sensitive marker for identifying potential influenza cases,
[24] this may have missed patients with influenza who did not report a cough at the time of 
presentation. Finally, when extrapolating from our US Flu VE Network enrollees to the 
entire source population, we assumed that patients who were not assigned a MAARI ICD 
code did not have influenza, unless they were enrolled and tested positive. This may 
underestimate the burden of medically-attended influenza.
Despite their limitations,[25] influenza vaccines remain the best available tool for reducing 
the risk of influenza disease. Our study suggest that the United States influenza vaccination 
program is leading to modest but meaningful reductions in ambulatory care visits for 
influenza, even in years when the vaccine is not well-matched to the dominant circulating 
influenza strain.
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Figure 1. 
A) Influenza cases identified by surveillance; B) Incidence of medically attended influenza 
by age group; C) Incidence of medically attended influenza by study site
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Figure 2. 
A) Estimated influenza vaccine effectiveness (VE); B) Estimated cases averted per 1,000 
vaccinees, by age group; C) Estimated cases averted per 1,000 vaccinees, by study site
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